Duchenne muscular dystrophy leads to cardiomyopathy. The objective of this study was to estimate the association of body mass index with cardiomyopathy onset. Cardiomyopathy was defined as left ventricular ejection fraction <55% or left ventricular fractional shortening <28%. Overall, 48% met the criteria for cardiomyopathy. We were unable to demonstrate an association between body mass index Z score and age of cardiomyopathy onset (hazard ratio 0.79, 95% confidence interval 0.57-1.11, P ¼ .17) after adjusting for covariates. Duration of corticosteroid use (P ¼ .01), but not loss of ambulatory ability (P ¼ .47), was associated with age of cardiomyopathy onset. We were unable to detect a significant difference in median body mass index Z scores in corticosteroid-treated boys compared with corticosteroid-naïve boys (1.11, 95% confidence interval 0.25-1.95, vs 1.05, 95% confidence interval 0.01-1.86, P ¼ .69). No association was detected between the body mass index Z scores of Duchenne muscular dystrophy subjects and age of cardiomyopathy onset.
The disease course is one of progressive muscle injury and weakness, leading affected boys to experience loss of ambulation and the eventual development of respiratory and cardiac failure. Death now typically occurs in the third decade. No cure exists for Duchenne muscular dystrophy.
Duchenne muscular dystrophy cardiomyopathy is defined by myocardial fibrosis contributing to ventricular dysfunction. 4 Most boys remain asymptomatic in the early stages of declining cardiac function, making it very difficult to apply symptom-based classification systems such as the New York Heart Association (NYHA). 4 The majority of boys with Duchenne muscular dystrophy will have evidence of cardiomyopathy, or altered ventricular function, by the age of 20 years. 1, 5 A certain subset, however, has evidence of the development of altered ventricular function in the late first or early second decades. Research aimed at identifying modifiable predictors for early-onset cardiomyopathy is clinically relevant. Conflicting evidence exists regarding the interaction between cardiac function 6, 7 and skeletal muscle function; animal and human research studies have shown influences to be both beneficial and detrimental. Adult studies have shown obesity to be a risk factor in both the progression of heart failure and to have direct myocardial effects in diabetic and hypertrophic cardiomyopathies 8, 9 ; however, there are limited studies on the interaction between weight and cardiovascular risk in children. [10] [11] [12] Obesity is prevalent in Duchenne muscular dystrophy secondary to lack of mobility and corticosteroid use, which is associated with similar metabolic derangement seen in adult studies.
Our study aimed to characterize the association of body habitus with age of cardiomyopathy onset in Duchenne muscular dystrophy. We sought to determine if body habitus and the current medical regimen used in Duchenne muscular dystrophy patients is associated with the age of cardiomyopathy onset. We tested the hypothesis that higher body mass index (BMI) would have negative cardiovascular associations and would be associated with earlier onset of cardiomyopathy in Duchenne muscular dystrophy-affected boys. Secondarily, we tested the association of treatment with corticosteroids and body mass index and cardiomyopathy onset.
Methods

Study Design and Recruitment
After local institutional review board approval, we conducted a retrospective cohort study over a 6-year time period (2007) (2008) (2009) (2010) (2011) (2012) (2013) . Subjects included boys with confirmed Duchenne muscular dystrophy by either genetic testing or a muscle biopsy with a corresponding skeletal muscle phenotype followed in a combined Neuromuscular-Cardiology clinic at a single institution. All subjects had undergone cardiac imaging (either an echocardiogram or cardiac magnetic resonance imaging) at our institution over the study period. A total of 85 boys met the inclusion criteria with complete data.
Study Protocol
After subject identification, cardiac imaging was reviewed for each subject. At our institution, cardiac imaging was routinely performed on either an annual or biannual basis. The cardiac imaging modalities reviewed for this study included echocardiography and cardiac magnetic resonance imaging. Imaging measurements collected included left ventricular ejection fraction, left ventricular fractional shortening, internal dimension of the left ventricle in diastole, internal dimension of the left ventricle in systole, and left ventricular mass. Because of the small number of subjects with complete cardiac magnetic resonance data at the time of the study (26 total over the study period), echocardiographic imaging measurements were used for the primary analysis, unless otherwise indicated. Cardiomyopathy was defined as either a left ventricular ejection fraction <55% or left ventricular fractional shortening <28%. Cardiomyopathy development was considered premature if a subject aged 15 years or younger had abnormal ventricular function by the above measurements. Because of imaging quality, when a subject lacked a measurable left ventricular ejection fraction on the echocardiographic studies reviewed; the left ventricular fractional shortening was used as the main outcome measure to define cardiomyopathy. Each subject's baseline study (defined as the first study performed) was documented as the initial visit; all subsequent studies and their measures were recorded until either the criteria for cardiomyopathy was met or that subject's most recent study was reached. If a subject did not have consecutive visits recorded, it was decided to include the subject in the cohort, as it was felt by the research team that their imaging and body habitus information strengthened the overall study. The subject's height and weight were recorded at the time of the imaging study with a postanalysis-calculated body surface area (calculated as square root of height [cm] Â weight [kg] / 60) and body mass index (calculated as weight [kg]/ height 2 [cm]). Body mass index Z scores were also calculated based on the Centers for Disease Control and Prevention (CDC) body mass index-for-age growth charts. Baseline characteristics collected included cardiac medication usage and corticosteroid usage and duration. Timing of cardiac medication initiation was at the discretion of the attending physician and family, but was based on the current evidence-based recommendations aimed at a proactive management approach. There was limited practice variability, as there was only 1 treating physician for the majority of subjects. The age of loss of ambulation for each patient, if reached during the study period, was documented longitudinally. The last imaging study prior to death was documented in those patients in whom death occurred during the study period. A subject was considered to be corticosteroid-naïve if he received treatment for less than 6 months.
Statistical Analysis
Descriptive techniques were reported as median (interquartile range) for continuous variables and frequency (percentage) for categorical variables. Linear models accounting for repeated measurements using generalized least squares were used to estimate the association of body mass index Z scores over time on the percentage change of left ventricular fractional shortening or internal dimension of the left ventricle in diastole after adjusting for covariates (duration of corticosteroid usage, and whether loss of ambulation had occurred or not). Proportional hazard regression with time-dependent covariates was used to assess if body mass index Z score had an association with age of cardiomyopathy onset. Interval censoring was used where each subject was considered at risk from the time of the first visit until cardiomyopathy onset or they were censored. Subjects were censored at their time of death or last visit. To incorporate the time-varying covariate, we divided time into 1-year intervals and included covariates for whether the subject was ambulatory and spline of body mass index Z score during that year (body mass index Z score is lagged by 1 year). The duration of steroid use and whether loss of ambulation had occurred or not was adjusted for in the model. Spearman correlation coefficients were calculated between duration of steroid use and body mass index measurements. R statistical software (version 2013) was used for the statistical analysis. Two-sided P values <.05 were considered statistically significant.
Results
Baseline Results
A total of 85 boys with confirmed Duchenne muscular dystrophy were included (Tables 1 and 2 ). Overall, 48% (41/85) of boys met criteria for cardiomyopathy by the end of the study period, with the average age of onset of 15.8 years (range 9 to 29 years). Almost 73% of boys were treated with corticosteroids at some point during the disease course (62/85), with a median treatment duration of 4 years. At the time of cardiomyopathy development, 37% of boys (15/41) were receiving corticosteroids. A total of 8 deaths (9% rate of death) occurred in the cohort during the study period. Duchenne muscular dystrophy boys did not exhibit significant changes in weight over the study period. The majority of boys fell into the normal-weight category (body mass index for age between 5% and 85% [31/85]) or the overweight/obese weight category (body mass index for age greater than 85% [46/85]). Only 9% (8/85) of boys were classified in the underweight category (a body mass index for age less than 5%). We did not detect a difference in cardiomyopathy development between weight categories (P ¼ .81). For those that met criteria for cardiomyopathy, the majority fell into either the normal weight (32%, 13/41) or overweight (42%, 17/41) categories at the time of diagnosis. The underweight category was represented in 10% (4/41) of boys. No difference was detected in the age of cardiomyopathy onset between boys who changed weight categories the year prior to cardiomyopathy onset (median age of 14.5 years) compared with those who did not change weight category (median age 14.25). Independent of cardiomyopathy onset, in those boys with documented consecutive yearly visits, 67% (44/66) had no change in their weight category between years. In boys who shifted weight categories between any 2-year period, weight loss (13/66) was more prevalent than weight gain (9/66).
Generalized Linear Model Results
No significant difference was detected between body mass index Z score and percent change of left ventricular fractional shortening (P ¼ .35, 95% confidence interval, 1.90-0.71) or internal dimension of the left ventricle in diastole over time (P ¼ .25, 95% confidence interval, 0.73-0.47), adjusting for duration of corticosteroid usage and whether loss of ambulation had occurred or not.
Corticosteroid Results
Affected boys who received corticosteroids for >6 months did not differ significantly in their median body mass index Z scores (1.11, interquartile range 0.25, 1.95) compared to corticosteroid-naïve subjects (1.05, interquartile range 0.01, 1.86; P ¼ .69) (Figure 1 ). We were also unable to correlate continued corticosteroid use until the time of cardiomyopathy diagnosis to median body mass index Z score (1.12, interquartile range 0.25, 1.84, vs 1.07, interquartile range 0.04, 1.97; P ¼ .67). There was a weak positive correlation between corticosteroid duration and body mass index Z score (r ¼ 0.05) .
Proportional Hazard Regression With Time-Dependent Covariates Model
We did not detect a significant association with body habitus (as studied using the body mass index Z score) and earlier onset of cardiomyopathy in our cohort (Figure 2 ). After adjusting for covariates (duration of corticosteroid usage and whether loss of ambulation had occurred or not), we did not detect a significant association between the subject's body mass index Z score and age of cardiomyopathy onset (hazard ratio 0.79, when increased from 25th percentile [Z score of 0.17] to 75th percentile [Z score of 1.93], 95% confidence interval 0.57-1.11, P ¼ .17). Two factors, corticosteroid usage and loss of ambulation, were evaluated for association to cardiomyopathy onset in our cohort. The duration of corticosteroid usage (hazard ratio 0.4 when increased from 25th percentile [2 years] to 75th percentile [6 years], 95% confidence interval 0.2-0.82; P ¼ .01) correlated with delayed cardiomyopathy onset. Whether loss of ambulation occurred or not during the study period was not significantly associated with a change in left ventricular fractional shortening (P ¼ .42) or internal dimension of the left ventricle in diastole (P ¼ .28).
Discussion
We were unable to identify an association between the body habitus of Duchenne muscular dystrophy subjects and their age of cardiomyopathy onset, although we cannot exclude the possibility that the size of our cohort did not provide adequate statistical power to detect a small but nonetheless meaningful association. We were also unable to confirm our secondary hypothesis, that higher body mass index Z scores would be observed in those boys treated with corticosteroids for more than 6 months. We confirmed a previously known association with cardiomyopathy onset and duration of steroid use; a longer duration of use is associated with a later age of development of cardiomyopathy. We were unable to show a correlation between loss of ambulation and cardiomyopathy onset in our cohort, however. These findings are important because they suggest that body habitus may not be associated with earlier cardiomyopathy development in Duchenne muscular dystrophy; however, additional research is needed to corroborate these results and to rule out the possibility of meaningful associations via more precise confidence intervals. Duchenne muscular dystrophy cardiomyopathy is common, with more than 50% of boys exhibiting evidence of cardiomyopathy by the end of their second decade. 1, 5 Proactive medical therapies, such as angiotensin-converting enzyme inhibitors, beta-blockers, and aldosterone antagonists, can be useful in the treatment of Duchenne muscular dystrophy-associated cardiomyopathy 1, [13] [14] [15] [16] and have been shown to lessen myocardial fibrosis in animal models. 8 Corticosteroids, widely used to prolong ambulation, 14 have been shown to have beneficial effects on cardiac function and cardiovascular mortality. 17, 18 Our study confirmed findings that previously demonstrate the beneficial effects of corticosteroids on the rate of cardiomyopathy progression. 18 These results served to further validate our other findings.
We were unable to demonstrate an association between body habitus and premature onset of cardiomyopathy within our patient population. We chose to use a subject's body mass index Z score as the independent variable, instead of the body surface area or body mass index, to more uniformly describe the standard deviation within the cohort and to allow for statistical comparisons between the group means. 19 The modality used to assess cardiac function in our study was echocardiography, as it provided the most complete data. Cardiac magnetic resonance has been frequently used in this population and likely provides a more accurate and reproducible assessment of cardiac function, as well as an assessment of myocardial fibrosis. Although left ventricular fractional shortening has adequately correlated with cardiac magnetic resonance left ventricular ejection fraction in previous studies, 20 replicating this study using cardiac magnetic resonance as the main assessment of cardiac function could be performed in a future research project.
No discernable differences were seen in the body habitus compositions between those boys who developed cardiomyopathy and those with preserved cardiac function. Interestingly, boys' weights (and body mass index Z scores) remained relatively stable between years, with only 28% (26/ 92) showing a change in their weight category during the study period. This stability may be impacted by the study duration, high usage of corticosteroids by our cohort, and degree of baseline muscle strength secondary to the juvenile average age of the cohort.
Recent studies in the mdx mouse model of Duchenne muscular dystrophy have raised concerns that corticosteroids could worsen myocardial fibrosis. These concerns, combined with the weight gain associated with systemic corticosteroids, 21 have prompted some to question the safety of long-term use. Interestingly, we were unable to show a difference in body mass index Z scores among those boys with a past history of corticosteroid use compared to those without. In addition, our results suggested that the consequence of weight gain might not be as considerable as previously thought, thus allaying some of the fears about long-term use of corticosteroids in Duchenne muscular dystrophy.
Certain limitations were inherent to our study. As our study population was modest, the study suffers from lack of precision for many estimates because of the sample size; including the less severe forms of muscle disease would have increased precision but would have limited the application of results and the generalizability of the findings. The lack of power could have also increased the likelihood of a type II error, but because of the rare nature of the disease, including an adequately sized cohort was not feasible without a larger-scale multicenter study. In addition, the age of our cohort may have limited the analysis; however, we had a considerable proportion of affected boys who developed our primary outcome of cardiomyopathy over the study period and are able to document weight patterns over multiple years for the subjects. Another limitation involved the use and predictive capacity of body mass index Z scores as a surrogate for weight change in muscle wasting diseases. Other studies involving Duchenne muscular dystrophy patients have used weight for age ratio, 22 urinary creatinine excretion, 23 and MRI resting energy expenditure 24 to study weight change over time. The retrospective nature of our study did not allow the use of these alternative methods, though these approaches may prove useful in conducting future prospective studies. We are unable to comment on the degree of cardiomyopathy progression to clinical heart failure after the initial abnormal echocardiogram as we elected to study until cardiomyopathy onset; it is possible that body mass index plays a larger role in cardiomyopathy progression in older subjects or subjects with already depressed left ventricular function. The high prevalence of corticosteroid use could have led to confounding in both the age of cardiomyopathy onset and weight trends in the overall cohort. Because of the retrospective nature of the study, we did not have complete data on cardiac medication usage for this cohort and removing those patients would have further reduced the study power. However, the same physician treated all patients, leading to very little practice variability.
No association was demonstrated between the body mass index of Duchenne muscular dystrophy subjects and their age of cardiomyopathy onset. The clinical significance of this result, however, warrants ongoing investigation, as this study describes novel findings. A correlation between cardiomyopathy onset and corticosteroid usage was demonstrated in the cohort. Further research is needed to identify factors predictive of premature cardiomyopathy onset in Duchenne muscular dystrophy boys, as significant advances in cardiac understanding and management are required. Future work is necessary to evaluate whether weight changes due to change in muscle mass or interventions for elevated body mass index can alter the progression to cardiomyopathy.
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